Fagron NV (FAGR.BR)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Rafael Padilla | CEO & Executive Director | 2.66M | -- | 1978 |
Ms. Karin de Jong | CFO & Executive Director | 1.48M | -- | 1979 |
Ms. Vera Bakker | Chief Operating Officer | 7.5k | -- | 1972 |
Mr. Johan Verlinden | Head of Legal, Mergers & Acquisitions | -- | -- | -- |
Fagron NV
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 3,828
Description
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Corporate Governance
Upcoming Events
July 31, 2025 at 6:30 AM UTC
Fagron NV Earnings Date
Recent Events
May 19, 2025 at 12:00 AM UTC
Ex-Dividend Date